The estimated Net Worth of Angie You is at least 1.32 百万$ dollars as of 8 March 2017. Angie You owns over 30,000 units of Oric Pharmaceuticals stock worth over 1,319,195$ and over the last 8 years Angie sold ORIC stock worth over 0$.
Sign up
Angie You ORIC stock SEC Form 4 insiders trading
Angie has made over 1 trades of the Oric Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Angie bought 30,000 units of ORIC stock worth 42,900$ on 8 March 2017.
The largest trade Angie's ever made was buying 30,000 units of Oric Pharmaceuticals stock on 8 March 2017 worth over 42,900$. On average, Angie trades about 4,286 units every 0 days since 2017. As of 8 March 2017 Angie still owns at least 133,252 units of Oric Pharmaceuticals stock.
You can see the complete history of Angie You stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Angie You's mailing address?
Angie's mailing address filed with the SEC is C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Oric Pharmaceuticals
Over the last 5 years, insiders at Oric Pharmaceuticals have traded over 33,873,532$ worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth 12,330,600$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of 996,237$. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth 76,875$.
What does Oric Pharmaceuticals do?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
What does Oric Pharmaceuticals's logo look like?
Complete history of Angie You stock trades at Sierra Oncology Inc、Oric Pharmaceuticals
Oric Pharmaceuticals executives and stock owners
Oric Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Jacob M. Chacko M.B.A., M.D.,
Pres, CEO & Director -
Dr. Pratik S. Multani M.D., M.S.,
Chief Medical Officer -
Dr. Pratik S. Multani,
Chief Medical Officer -
Dominic G. Piscitelli CPA, M.B.A., CPA,
Chief Financial Officer -
Dr. Richard A. Heyman Ph.D.,
Co-Founder, Independent Chairman & Member of Scientific Advisory Board -
Dr. Christian V. Kuhlen Esq., J.D., M.D.,
Gen. Counsel -
Matthew Panuwat,
Chief Bus. Officer -
Dr. Edna Chow Maneval,
Sr. VP of Clinical Devel. -
Dr. Christian V. Kuhlen J.D., M.D., Esq.,
Gen. Counsel -
Dr. Lori Sickels Friedman Ph.D.,
Chief Scientific Officer -
Dr. Scott W. Lowe Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Mardi Dier,
-
Richard A. Heyman,
-
Peter Svennilson,
Director -
Group Ii, Lp Column Group I...,
-
Dominic Piscitelli,
Chief Financial Officer -
Fund L.P.Topspin Biotech Fu...,
-
Richard H Scheller,
Director -
Advisors Llc Orbi Med Capit...,
-
Pratik S Multani,
Chief Medical Officer -
Carl L Gordon,
Director -
Steven L. Hoerter,
-
Angie You,
-
Group Ii, Lp Column Group I...,
-
Jacob Chacko,
PRESIDENT AND CEO -
Lori Anne Kunkel,